News
Look out Dupixent, Lilly's lebrikizumab is on the march
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner.
Friday 3 April 2026
